Korean Market
OWNR
NGeneBio
★

SH Healthcare Investment Reports 21.95% Stake in NGeneBio After 3:1 Reverse Split

 
OWNR
NGeneBio
★

NGeneBio 3:1 Reverse Stock Split Reduces Outstanding Shares by 66.7%, Largest Shareholder Stake Unchanged

 
EXCH
NGeneBio
★

NGeneBio Trading Halt Due to Capital Reduction, Suspended Until New Share Listing

 
ISSU
NGeneBio
★★★

NGeneBio Announces Massive 80% Dilutive Rights Offering…Severe Equity Dilution and Financial Risk

 
EXCH
NGeneBio
★

NGeneBio Shareholders Approve 66.67% Free Reduction to Offset Deficit, Raising Concerns Over Shareholder Value

 
OWNR
NGeneBio
★★

66.67% Capital Reduction via 3:1 Stock Consolidation to Cover Deficits

 
OTHR
NGeneBio
★★★★

NGeneBio Decides 66.67% Capital Reduction, Merging 3 Shares into 1

 
ISSU
NGeneBio
★★★★

NGeneBio Announces 22.4 Billion Won Rights Offering, Diluting Existing Shares by 80.01%

 
EXCH
NGeneBio
★

Record Date Set for Extraordinary General Meeting (2026-05-12)

 
EXCH
NGeneBio
★★★★★

Trading Suspension Due to Capital Reduction

 
MATR
NGeneBio
★

Capital Reduction to Cover Deficits, No Specific Ratio Disclosed

 
EXCH
NGeneBio
★★

Extraordinary General Meeting to Approve Capital Reduction for Deficit Coverage

 
MATR
NGeneBio
★

Rights Offering at 0.8 New Shares per Existing Share After 3:1 Reverse Stock Split

 
PERI
NGeneBio
★

NGeneBio Q1 2026 Revenue Surges (Merger Effect) but Losses Continue; Decides Reverse Stock Split and Rights Offering to Improve Financial Structure